Breaking News
1 hour ago
Pharma Now Editorial Team

Pharma Now Editorial Team
Pharma Now Editorial Team
Pharma Now Editorial Team
Miv-cel hits 46% median walk improvement in SPS phase 2, raising GMP readiness questions for autologous CAR-T manufacturers.
Pharma Now Editorial Team

Exciva doses first SERENADA trial patient as EUR 53M Series B closes, raising CNS manufacturing and QA planning questions.
Pharma Now Editorial Team

Pfizer's Delaware patent settlements extend VYNDAMAX US exclusivity to June 2031, reshaping generic tafamidis entry timelines.
Pharma Now Editorial Team

PHARMAP 2026 in Amsterdam convenes senior pharma leaders on Pharma 4.0, smart manufacturing, supply chain resilience, and patient‑centric packaging innovation.
Team Pharma Now